Modeling the Cost-Effectiveness of Novel Direct Acting Antiviral (DAA) Treatments In Patients Co-Infected with Hepatitis C Virus (Hcv) and Human Immunodeficiency Virus (HIV)
May 1, 2015, 00:00
10.1016/j.jval.2015.03.1391
https://www.valueinhealthjournal.com/article/S1098-3015(15)01448-5/fulltext
Title :
Modeling the Cost-Effectiveness of Novel Direct Acting Antiviral (DAA) Treatments In Patients Co-Infected with Hepatitis C Virus (Hcv) and Human Immunodeficiency Virus (HIV)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01448-5&doi=10.1016/j.jval.2015.03.1391
First page :
A239
Section Title :
Infection
Open access? :
No
Section Order :
855